GLPG NA
Galapagos NV
Healthcare
08/04/2015
Presented
| Date | 07/31/2015 |
| Price | €54.63 |
| Market Cap | $1.83B |
| Ent Value | $2.13B |
| P/E Ratio | N/A |
| Book Value | €6.80 |
| Div Yield | N/A |
| Shares O/S | 38.89M |
| Ave Daily Vol | 340,000 |
| Short Int | N/A |
Current
| Price | €27.16 |
| Market Cap | $1.99B |
| Galapagos NV, a clinical stage biotech company, develops and commercializes novel medicines in Belgium, Croatia, France, and the Netherlands. Its products include GLPG0634, an orally-available selective inhibitor of Janus kinase 1, which is in Phase II clinical study for the treatment of rheumatoid arthritis and other inflammatory diseases; and GLPG1205/GLPG1690 that is in Phase IIA clinical study for treating inflammatory bowel disease, as well as in Phase II proof-of-concept study for the treatment of ulcerative colitis patients. The company is also developing MOR106, an antibody, which is in preclinical development stage for the treatment of inflammatory diseases; GSK2586184, an investigational compound that is in Phase II clinical study for the treatment of chronic immuno-inflammatory diseases consisting of SLE, psoriasis, and ulcerative colitis; and GLPG0974, an orally available small molecule, which is in Phase II clinical study to prevent free fatty acid-induced activation and migration of neutrophils towards an inflammatory site, such as in the gut of patients with inflammatory bowel disease. It has strategic alliances with GlaxoSmithKline, MorphoSys, Servier, and AbbVie to discover and develop small molecules for the treatment of inflammation, inflammatory diseases, osteoarthritis, oncology, rheumatoid arthritis/crohn’s disease, and cystic fibrosis diseases. The company was founded in 1999 and is headquartered in Mechelen, Belgium. |
Publicly traded companies mentioned herein: AbbVie Inc (ABBV), Galapagos NV (GLPG NA), Johnson & Johnson (JNJ), Vertex Pharmaceuticals Inc (VRTX)
Highlights
The presenter began by saying, “Nobody wanted to have a discussion about Galapagos NV (GLPG) 12 months ago, but today their oral JAK1-inhibitor Filgotinib (GLPG0634) is generating a lot of positive data compared to injectables and the early stage Cystic Fibrosis (CF) trials look promising”. He is long the stock and sees substantial upside potential from current levels (~54 euros) as the pipeline matures. In addition, the company’s partner on both Filgotinib and CF is AbbVie (ABBV). A participant who agreed with the bullish view stated, "GLPG might be ABBV's best pipeline asset".
◆Signing up and creating account with us unlocks this content for you. Contact us today for full access to DeMatteo Research and more.
◆Signing up and creating account with us unlocks this content for you. Contact us today for full access to DeMatteo Research and more.